Every 10-Q that Pyxis Oncology, Inc. (PYXS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PYXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PYXS filings page.
Pyxis Oncology, Inc. reported a net loss of $25.3 million for the quarter and $48.6 million for the six months ended June 30 2026, with an accumulated deficit of $491.8 million. Cash, cash equivalents and marketable debt securities totaled $33.0 million at quarter end, and management stated there is substantial doubt about the company’s ability to continue as a going concern over the next year without additional financing.
Subsequent to quarter end, Pyxis closed a private placement raising gross proceeds of approximately $50 million and issued common warrants that could provide up to about $64 million more if exercised for cash, which together are expected to fund operations into the second quarter of 2027. The company remains a clinical‑stage oncology business focused on its lead antibody‑drug conjugate MICVO for recurrent and metastatic head and neck squamous cell carcinoma, with ongoing Phase 1 monotherapy and combination studies showing encouraging objective response and disease control rates in heavily pre‑treated patients.
Pyxis Oncology reported a net loss of $23.3 million for the quarter ended March 31, 2026, slightly higher than the $21.2 million loss a year earlier, as it increased spending on its lead cancer drug candidate MICVO.
Research and development expenses rose to $20.0 million, driven mainly by higher clinical trial and preclinical costs for MICVO monotherapy and combination studies. General and administrative expenses fell to $4.4 million, largely due to lower stock-based compensation.
Pyxis ended the quarter with $41.0 million in cash, cash equivalents and marketable debt securities and an accumulated deficit of $466.4 million. Management states there is substantial doubt about the company’s ability to continue as a going concern beyond the next 12 months without additional financing, despite having an effective $350.0 million shelf registration and $150.0 million at-the-market capacity.
Pyxis Oncology (PYXS) reported Q3 2025 results, highlighting ongoing R&D investment and a going concern warning. The company posted a net loss of $22.0 million for the quarter on zero revenue. Operating expenses were $23.5 million, including $17.8 million in research and development and $5.7 million in general and administrative costs.
As of September 30, 2025, Pyxis held $76.3 million in cash, cash equivalents, and short‑term investments, with total assets of $105.6 million and stockholders’ equity of $68.8 million. Net cash used in operating activities was $53.1 million for the nine months ended September 30, 2025. The company disclosed that current liquidity will not be sufficient to fund operations over the next 12 months, which raises substantial doubt about its ability to continue as a going concern.
Pipeline updates center on micvotabart pelidotin (MICVO). The FDA granted Fast Track Designation in February 2025 for recurrent/metastatic HNSCC monotherapy after platinum and anti‑PD-(L)1 therapy. Pyxis recognized $2.8 million in milestone revenue in the nine‑month period tied to Suvemcitug approval in China. Common shares outstanding were 62,264,215 as of October 31, 2025.
Pyxis Oncology (PYXS) is a clinical-stage oncology company focused on micvotabart pelidotin and reports significant historical losses with the expectation of continued losses while it advances development. The company has 62,018,135 shares outstanding as of June 30, 2025 and 190,000,000 shares authorized. It states a need for substantial additional capital and that failure to raise funds could delay or cut research, development or commercialization efforts. Preclinical and early clinical signals for micvotabart pelidotin are highlighted: robust tumor growth inhibition across patient-derived xenograft models, complete responses in multiple indications, tolerability in animal studies, and enhanced efficacy in combination with anti-PD-1. The company plans two ~20-patient expansion cohorts at 5.4 mg/kg IV Q3W with preliminary data expected in the second half of 2025 and the first half of 2026. Material business risks include regulatory, manufacturing, intellectual property and third-party reliance, and the company recorded no federal income tax provision for recent periods.